Tretten Approval History
FDA Approved: Yes (First approved December 23, 2013)
Brand name: Tretten
Generic name: coagulation factor XIII A-subunit (recombinant)
Company: Novo Nordisk
Treatment for: Factor XIII A-Subunit Deficiency
Tretten (coagulation factor XIII A-subunit (recombinant)) is a recombinant analogue of the human Factor XIII A-subunit for the prevention of bleeding in patients who have the rare clotting disorder congenital Factor XIII A-subunit deficiency.
Development History and FDA Approval Process for Tretten
|Dec 23, 2013||FDA Approves Tretten to Treat Rare Genetic Clotting Disorder|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.